ReviewFrontiers in pharmacology2026
Therapeutic potential and molecular mechanisms of citrus flavonoids in hepatocellular carcinoma.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Citrus-derived flavonoids, particularly naringenin, hesperidin, and hesperetin, have emerged as promising bioactive compounds with potential therapeutic relevance in hepatocellular carcinoma (HCC). This review provides a focused synthesis of current preclinical evidence regarding their anticancer properties and underlying molecular mechanisms in experimental HCC models. These flavonoids exert broad anticancer effects, including inhibition of cell proliferation, induction of apoptosis, reduction of oxidative stress, and suppression of tumor progression and metastasis. These activities are mediated through modulation of key oncogenic signaling pathways, which are critically involved in hepatocarcinogenesis. In addition, citrus flavonoids influence mitochondrial function and cellular redox homeostasis, thereby contributing to programmed cell death and metabolic regulation. Preclinical studies further indicate that these compounds may enhance the efficacy of conventional chemotherapeutic agents, including cisplatin, doxorubicin, and sorafenib, while exhibiting reduced toxicity toward normal cells. Moreover, nanoformulation-based delivery systems have been shown to improve their bioavailability and therapeutic performance in experimental models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.